Contact
Please use this form to send email to PR contact of this press release:
Mereo BioPharma Receives FDA Rare Pediatric Disease Designation for Setrusumab for the Treatment of Osteogenesis Imperfecta
TO:
Please use this form to send email to PR contact of this press release:
Mereo BioPharma Receives FDA Rare Pediatric Disease Designation for Setrusumab for the Treatment of Osteogenesis Imperfecta
TO: